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Biomarkers in Environmental Toxicology: State of the Art
Philippe Grandjean, Stanley S. Brown,2 Phil Reavey,3 and Donald S. Young4
Together with many other research-based disci-
plines, environmental toxicology has profoundly bene-
fited from recent advances in molecular biology and
analytical chemistry. As a result of these accomplish-
ments, clinical and experimental studies of biomarkers
have developed into a multidisciplinary research area.
The IFCC has convened two conferences: to review
biomarkers of chemical exposure, in the first confer-
ence, and biomarkers of effects and of susceptibility, in
the second. As in the first conference, the second
meeting included 16 plenary presentations, all of which
are published in this special issue of Clinical Chemis-
try. Ninety posters were selected for display at the
conference and, on the basis of the quality of the poster
abstracts, the Organizing Committee chose 13 of these
for publication as extended abstracts in this issue. The
present overview is a summary of controversies and
conclusions that emerged during discussions at the
roundtable discussion sessions.
Biomarkers of Complex Effects
Environmental toxicology deals with complex inter-
actions between thousands of environmental chemicals
and a multitude of potential adverse effects. When a
single xenobiotic has different targets, a biomarker
may exist that reflects the integrated response of the
organism. However, a particular marker is likely to
represent only one individual toxic pathway. Nonethe-
less, the expression of early changes in one organ
system could well correlate with changes in other
systems. Thus, the accumulation of zinc protoporphy-
rim in erythrocytes during increased lead exposure is
due to toxic effects on heme biosynthesis, but it may
also represent a useful biomarker of overall toxicity
caused by the exposure. Unfortunately, examples of
such biomarkers are few, and it is not likely that
research in this field will be as productive as efforts to
obtain an improved understanding of mechanisms of
toxicity.
Different chemicals may have the same target, the
best known example from environmental toxicology
probably being acetylcholine esterase. In this case,
changes in the biomarker will represent the integrated
response to a possible array of exposures that act on
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the same target. In a more general sense, actions
caused by individual xenobiotics at the molecular level
may trigger a cascade of biochemical and physiological
effects, and some of the reactions may be common to
different etiological agents. Biomarkers of the inte-
grated exposure or integrated response may then be
developed. Relevant examples include carboxyhemo-
globin in blood as a biomarker of exposure to carbon
monoxide or methylene chloride, urinary dialkylphos-
phate excretion after exposure to common organophos-
phorus pesticides, and urinary mercapturates as a
marker of exposure to certain electrophilic compounds.
However, the biochemical mechanisms must be under-
stood to allow proper interpretation of this type of
information. Some such integrated biomarkers may be
too far down the toxic chain reaction to be useful for
preventive purposes. For example, a general toxic ef-
fect is the intracellular accumulation of calcium that
precedes cell death. Although probably a common
event in many toxic reactions, its usefulness as a
biomarker is limited by serious cellular damage having
already occurred by the time a significant change can
be detected. Research in this area needs to be closely
linked to studies in mechanisms of action so as to
explore more effectively the potentials for development
of new biomarkers.
The hypothesis regarding estrogenic and other hor-
monal effects of environmental chemicals has attracted
much interest recently. Although such effects have
been demonstrated in experimental studies and in
some wildlife studies, their significance for human
health is still a matter of controversy. Nonetheless, this
research area is very promising and has stimulated the
development of new techniques. Serum hormone con-
centrations, e.g., of testosterone, estradiol, and prolac-
tin, may be useful as biomarkers. Other hormonal
effects may also occur because of interaction with
hormone receptors or effects on the metabolism of
individual hormones.
Genetic Biomarkers
Significant advances have been made in the develop-
ment of sensitive and specific DNA-based and other
genetic assays, as detailed in papers presented at this
conference. Extremely sensitive assays of DNA and
protein adducts are now available as biochemical
markers. Progress has also been made toward the
development of biological marker assays of accumu-
lated gene-specific and cell-specific adducts. Some of
these assays seem to have reached the stage of appli-
cability in human biomonitoring studies. Further de-
velopment is needed with regard to assays for nonphe-
notypically selectable mutations.
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This new technology allows determination of ex-
tremely small alterations at the cellular level, but the
significance of most of these changes is unknown.
Although such changes may be unwanted, they are not
necessarily hazardous. The range of normal variation
is often incompletely known, and the validity of a
reference interval, if at all available, must be carefully
considered. Timing or duration of exposure and timing
of sampling may affect the biomarker result. Inter- and
intraindividual variations depend on a spectrum of
determinants such as other exposures, circadian
rhythm, ethnicity, and constitutional factors including
age and sex. Hence, macromolecular adducts are a good
measure of exposure at the level of the individual, but
their utilization in the context of determination of risk
is problematic.
A major problem to be considered is that between
DNA damage and carcinogenesis lie important steps
that can significantly affect the dose-response rela-
tions, e.g., cell proliferation (mitogenesis) and “promo-
tion.” Better conceptual tools are needed for the incor-
poration of biomonitoring data in the risk assessment
process as well as for the development of methods to
observe and quantify markers of the different stages of
carcinogenesis.
Accordingly, we now have at our disposal powerful
methodologies for measuring biomarkers that reflect
the biologically active dose in humans. Such adduct
and mutation methodologies should be applied in the
context of well-designed population studies that must
(a) fulfill strict epidemiological criteria for quality and
efficiency and (b) include multiple endpoints, as well as
a range of additional biomarkers, such as measures of
the internal dose (e.g., urinary metabolites), and ge-
netic variations of metabolic capacity. In this way,
applications of currently available methodologies in
well-designed studies will shed important light on the
needs for future technological developments and
should be regarded as a high research priority.
In addition, with better knowledge concerning ge-
netic heterogeneities, biomarkers of genetic hypersus-
ceptibility are being developed. Much of the research in
this area has focused on classical phase I or phase II
metabolic enzymes, and a considerable number of poly-
morphisms have been already characterized. These
genotypes affect the metabolism of xenobiotics and
thereby the associated risk of adverse effects. Addi-
tional heterogeneities are likely to be discovered during
the next few years, and simple assays may well be
developed to determine individual sensitivity to many
specific environmental exposures.
ApplicationforPrevention
New biomarkers are urgently needed as an integral
tool in preventive medicine and environmental health.
Biomarkers can range from the very simple ones, such
as a blood hemoglobin measurement, to very complex
and expensive determinations, e.g., of DNA adducts.
The human genome project is likely to lead to the
development of simple and practical tests that will be
useful, especially for monitoring exposures to carcino-
gens and for assessing the carcinogenic and other toxic
risks to individuals. This technology should allow the
healthcare system to become more involved in disease
prevention.
For the assessment of individual risk from biomar-
ker results, the positive predictive value of the test
needs to be determined. An acceptable level for the
positive predictive value of a test will depend on the
action that would follow from the test result. For
example, if a positive test result would lead to an
intervention to prevent an outcome that is relatively
low-risk, then, relatively speaking, a lower positive
predictive value for the test may be acceptable. Con-
versely, if a positive test result would lead to an
intervention to prevent an outcome that is high-risk,
the test would need a high positive predictive value to
be acceptable. The negative predictive value of the test
should also be considered, because if it is high (regard-
less of the positive predictive value), it can be reassur-
ing for an individual with a negative test result. Un-
fortunately, while carcinogenic risk is of great clinical
importance, no single marker among the many assays
available is likely to be of general value. Nonetheless,
biomarkers with limited usefulness in the prediction
of individual risk may still be useful for population
studies.
The question of reference data must also be consid-
ered. As most biomarkers have been developed only
recently, data on unexposed populations are rarely
available for comparison. An individual may be his or
her own reference, if comparable data are available
both before and after the exposure occurred. In a
monitoring program, the frequency with which a bi-
omarker is to be determined must be considered also
from an economic viewpoint, as the cost of primary
prevention may be less than an extensive surveillance
program.
Biomarkers are routinely used to monitor exposures
in occupationally exposed populations. Administrative
limits, sometimes called biological exposure limits,
have been determined for the interpretation of such
measurements. These limits are based on accumulated
knowledge and obviously cannot take into account
risks yet unknown. Not surprisingly, the limits used in
different countries, e.g., for exposures to lead and
certain solvents, have generally been lowered during
recent years, usually because of better documentation
of toxic effects. Hypersusceptible subgroups may exist,
and their need for special protection ought to be taken
into account. If they cannot be safeguarded by the
designated exposure limit, then other protective means
must be adopted, while avoiding discrimination and
stigmatization. Unfortunately, occupational exposure
limits are of limited use with regard to environmental
exposures, which are likely to be longer term and may
affect large subgroups with decreased resistance
against toxicity. Moreover, the occupational exposure
limits are of little use for diagnostic purposes or inter-
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pretation of new or unsolved problems such as multiple
chemical sensitivities.
Biomarkers may also help in improving regulatory
risk assessment by validating presumptions of accept-
able (or unacceptable) allowable levels of exposure. For
example, the finding of a biomarker with a high posi-
tive predictive value for the outcome of concern in a
population with exposures below the allowable level (as
well as in populations with exposures above the allow-
able level) would indicate that the allowable exposure
level is not as protective as assumed.
In applying biomarkers in environmental health and
preventive medicine, ethical issues must be addressed.
The sampling procedure, the storage and analysis of
the sample, and the reporting and interpretation of the
result all raise potential ethical problems. The out-
comes of the genome project will emphasize these
issues, especially with regard to privacy and protection
against discrimination. The practices seem to vary
between occupational health and environmental
health, from country to country, and between different
cultures. Although no definite answers can be pro-
vided, a heightened awareness is needed, and solutions
must be found on the basis of cooperation between
responsible scientists and the stakeholders involved.
Research Recommendations
Although not necessarily agreed by all participants
in the meeting, the following conclusions derived from
the discussions at the Cannes conference:
1) Basic research into mechanisms of action, such as
interaction of environmental chemicals with hormone
receptors, and progression from mutation to cancer, is
needed to allow development of biomarkers and appro-
priate interpretation of the results.
2) Biomarker research in laboratory models is
needed to illuminate findings in humans. Extrapola-
tion across species should be done with caution. For
example, the caffeine test for CYP1A1 expression is a
good marker for enzyme induction in rats, but not in
humans, and the Ah receptor from various species
shows different affinity characteristics.
3) Given the large number of chemicals in environ-
mental exposures, biomarkers that reflect an inte-
grated effect on the body or an organ system would be
useful, but this research approach may not be very
fruitful because of the intrinsic complexities.
4) Although DNA-based biomarkers have been devel-
oped and refined considerably during recent years,
methodological development is especially needed with
regard to accumulated gene-specific and cell-specific
adducts and nonphenotypically selectable mutations.
5) Most of the currently available biomarkers have
not been evaluated in detail with regard to their
validity for practical applications in exposed human
populations, and appropriate reference intervals are
generally not available. Special efforts in this area are
therefore urgently needed to allow interpretation of the
data.
6) Appropriate human biological samples from well-
defined populations should be systematically stored for
future studies by analyses not necessarily developed as
yet and to enable studies of the relation to disease
outcomes in the future. National and international
agencies should cooperate to facilitate such work.
7) Applications of biomarkers are likely to be useful
in risk assessment efforts, and a strengthened research
program on the development and application of bi-
omarkers is therefore appropriate.
8) While we recognize that the solutions may be
complex, we must address ethical issues in all bi-
omarker research, and we must resolve potential
conflicts related to application of biomarkers in an
open forum.
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